Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL959364 | 0.90 | KDM4E (1.00) | KDM4EPOLBMAPTNPC1SMN1; SMN2 | |
| SCHEMBL29709972 | 0.90 | KDM4E (1.00) | KDM4EPOLBMAPTNPC1SMN1; SMN2 | |
| SCHEMBL19384339 | 0.81 | GABRA1 (0.60) | KDM4EPOLBMAPTSMN1; SMN2LMNA | |
| SCHEMBL4605496 | 0.81 | KDM4E (0.58) | KDM4EPOLBMAPTNPC1SMN1; SMN2 | |
| SCHEMBL618089 | 0.80 | POLB (0.58) | KDM4EPOLBMAPTNPC1SMN1; SMN2 | |
| SCHEMBL13720557 | 0.79 | POLB (1.00) | KDM4EPOLBSMN1; SMN2RAB9ALMNA | |
| SCHEMBL25205501 | 0.79 | KDM4E (0.58) | KDM4EPOLBMAPTNPC1SMN1; SMN2 | |
| SCHEMBL3810014 | 0.79 | KDM4E (0.58) | KDM4EPOLBMAPTNPC1SMN1; SMN2 | |
| SCHEMBL8249980 | 0.78 | KDM4E (0.74) | KDM4EPOLBMAPTNPC1SMN1; SMN2 | |
| SCHEMBL1579253 | 0.77 | KDM4E (0.52) | KDM4EPOLBNPC1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| EP-2821401-B1 | DIHYDROQUINOLINONE COMPOUNDS AS MODULATORS OF THE MUSCARININC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-09 | — | — | EP | disclosed |
| EP-2821401-B1 | DIHYDROQUINOLINONE COMPOUNDS AS MODULATORS OF THE MUSCARININC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-09 | — | — | EP | disclosed |
| US-9403802-B2 | Heterocyclic compound and use therefor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9403802-B2 | Heterocyclic compound and use therefor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9403802-B2 | Heterocyclic compound and use therefor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| US-8293744-B2 | Heterocyclic fused cinnoline M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120040978-A1 | Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040978-A1 | Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2398324-A1 | PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck Sharp & Dohme Corp. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20110301167-A1 | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-08 | — | — | US | disclosed |
| WO-2010096338-A1 | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2009053799-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS, S.A. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-6180630-B1 | USEFUL IN THE TREATMENT OF ANXIETY AND CONVULSIONS | MERCK SHARP & DOHME LIMITED (GB) | 2001-01-30 | — | — | US | disclosed |
| EP-0991652-A1 | TRICYCLIC PYRAZOLO-PYRIDAZINONE ANALOGUES AS GABA-A RECEPTOR LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999000391-A1 | TRICYCLIC PYRAZOLO-PYRIDAZINONE ANALOGUES AS GABA-A RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301167-A1 | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CNR1, MTNR1A | KDM4E 3560/4885POLB 4235/4885MAPT 903/4885 |
| US-20120040978-A1 | Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators | CHRM1, CNR1, CHRNA7 | KDM4E 3190/4885POLB 2784/4885MAPT 905/4885 |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | CHRM1, CHRM4, CHRM2 | KDM4E 1528/4885POLB 4138/4885MAPT 611/4885 |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | KDM4E 3835/4885POLB 3606/4885MAPT 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.